Step 1 topics → Reproductive → Cryptorchidism

Cryptorchidism

USMLE Step 1 trap: Limits cancer risk in cryptorchidism to the undescended testis, missing the elevated risk in the contralateral testis as well. Both the undescended and the contralateral normally descended testis have increased risk of germ cell tumor, suggesting a systemic gonadal dysgenesis rather than purely a local temperature effect.

Cryptorchidism means one or both testes failed to descend into the scrotum by the time of birth. USMLE Step 1 tests this from three main angles: natural history and intervention timing, long-term complications, and the workup when testes are bilaterally absent — and the most dangerous misconception is thinking orchiopexy normalizes cancer risk when it does not. It's the most common congenital genitourinary abnormality in males — about 3% of full-term and up to 30% of premature male infants are affected — and a significant portion resolve spontaneously by 3–6 months of age. The complication angle is where most of the high-yield material lives.

What makes this topic tricky is the cancer risk question. Students almost universally learn that the undescended testis has elevated cancer risk (true), but the exam wants you to know that the contralateral, normally descended testis also carries elevated risk — pointing to a systemic gonadal dysgenesis rather than a purely local temperature problem. The reflex answer that orchiopexy 'fixes' the cancer risk is also wrong; it improves fertility and enables surveillance but does not normalize malignancy risk.

The other high-yield trap is bilateral non-palpable testes. USMLE Step 1 will present a newborn where neither testis is palpable and expect you to recognize this is not just 'bilateral cryptorchidism' until proven otherwise — it could be anorchia or a disorder of sex development (like 46,XX CAH virilizing a genetic female). That means karyotype plus hormonal workup (FSH, LH, testosterone, AMH/inhibin B) before you assume anything.

From real student decks
70%have cards covering this topic
46%have mature cards

Common misconceptions

Common mistake
Wrong: Only the undescended testis has increased cancer risk in cryptorchidism.
Right: Both the undescended and the contralateral normally descended testis have increased risk of germ cell tumor, suggesting a systemic gonadal dysgenesis rather than purely a local temperature effect.
The 'heat damages the testis' model predicts only the retained testis should be at risk — but the contralateral descended testis also has elevated germ cell tumor risk, which that model can't explain. This points to an underlying abnormality in gonadal development (gonadal dysgenesis) affecting both testes from the start. On USMLE Step 1, if a question asks about cancer risk in a man with a history of unilateral cryptorchidism, the correct answer includes bilateral increased risk, not just the affected side.
Common mistake
Wrong: Orchiopexy eliminates the risk of testicular cancer.
Right: Orchiopexy (ideally before age 1–2) reduces but does not eliminate cancer risk; it primarily preserves fertility and allows easier tumor surveillance by placing the testis in the scrotum.
Orchiopexy moves the testis into the scrotum where its temperature is normalized and where it can be physically examined, but it does not correct the underlying gonadal abnormality that elevates cancer risk. Think of it as harm reduction and surveillance optimization rather than a cure. The primary proven benefits of early orchiopexy are improved spermatogenesis (fertility preservation) and the ability to palpate the testis for early tumor detection — not risk elimination.
Common mistake
Gap: Misses that bilateral non-palpable testes mandate karyotype and hormonal workup to exclude DSD before assuming cryptorchidism
Bilateral non-palpable testes require karyotype and hormonal evaluation (FSH, LH, testosterone, AMH/inhibin B) to distinguish bilateral cryptorchidism from anorchia or a disorder of sex development such as 46,XX CAH.
When both testes are non-palpable, you cannot assume bilateral cryptorchidism — the genetic sex of the infant may not match the external phenotype. A virilized 46,XX infant with CAH can appear to have cryptorchidism when in fact there are no testes at all. Karyotype tells you the genetic sex, AMH/inhibin B confirms whether testicular tissue exists, and FSH/LH/testosterone characterize the hypothalamic-pituitary-gonadal axis. Skipping this workup risks misdiagnosis of a DSD with significant management and social consequences.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the definition of cryptorchidism, when spontaneous descent can still occur (up to 6 months of age), and the recommended timing of orchiopexy (ideally by 6–18 months) to preserve fertility.
  2. Understand the long-term complications — infertility (from heat-related spermatogenic damage), germ cell tumor risk (seminoma most common), and torsion — and recognize that BOTH the undescended testis AND the contralateral normally descended testis carry elevated cancer risk.
  3. Know that orchiopexy reduces but does not eliminate testicular cancer risk; its main benefits are preserving fertility and allowing scrotal surveillance for tumors.
  4. Recognize that bilateral non-palpable testes in a newborn require karyotype and hormonal workup (FSH, LH, testosterone, AMH/inhibin B) to distinguish bilateral cryptorchidism from anorchia or a DSD such as 46,XX CAH before making any diagnosis.

Can you avoid these mistakes?

A 2-year-old boy has a left testis that is not palpable in the scrotum or inguinal canal. His right testis is normal. What is the most important long-term complication concern, and does it affect only the left side?
Parents of a boy who underwent orchiopexy at 14 months ask if their son's risk of testicular cancer is now the same as the general population. How do you counsel them?
A newborn phenotypically male infant has no palpable testes bilaterally. What is your initial workup, and why can't you simply diagnose bilateral cryptorchidism?
At what age should orchiopexy ideally be performed, and what is the primary reason — fertility preservation, cancer risk reduction, or both equally?

Related topics

Gonadal Differentiation (SRY, MIS, Testosterone) Müllerian vs Wolffian Duct Derivatives 5α-Reductase Deficiency Complete Androgen Insensitivity Syndrome (CAIS)

See how your Anki deck covers this topic.

Upload your deck for a free audit →